Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer
A phase 2 basket trial shows a clinically meaningful antitumor activity with this chemotherapy-free regimen in heavily pretreated patients with HER2-mutated metastatic breast cancer
Day: February 17, 2025